Emily Langley, MD
Allergy & Immunology · Charlotte, NCNPI 1962676726
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 987 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations.
Across 987 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$2K
- Pfizer$2K
- CSL Behring$1K
- Sanofi$1K
- plus $9K from 33 others
What the payments were for
- Consulting fees$2081%
- Food & beverage$20,82498%
- Education$1261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 153 | $3,297 |
| GSK | 157 | $2,276 |
| Regeneron Healthcare Solutions, Inc. | 69 | $2,107 |
| Pfizer | 113 | $1,546 |
| CSL Behring | 55 | $1,353 |
| Sanofi | 34 | $1,265 |
| Takeda Pharmaceuticals U.S.A., Inc. | 54 | $1,120 |
| Optinose US, Inc. | 39 | $1,000 |
| Grifols USA, LLC | 45 | $760 |
| Biocryst US Sales Co., LLC | 28 | $726 |
| Amgen | 28 | $634 |
| Kaleo, Inc. | 33 | $612 |
| ARS Pharmaceuticals Operations, Inc. | 18 | $493 |
| Novartis | 25 | $456 |
| Pharming Healthcare, Inc. | 12 | $411 |
| Genentech USA, Inc. | 21 | $374 |
| Regeneron | 3 | $362 |
| Alk-abello, Inc | 19 | $356 |
| ADMA Biomanufacturing LLC | 11 | $223 |
| Aytu Biopharma, Inc. | 7 | $217 |
| LEO Pharma Inc. | 4 | $212 |
| Ionis Pharmaceuticals, Inc. | 4 | $171 |
| Phadia US Inc. | 3 | $170 |
| Octapharma USA, Inc. | 7 | $161 |
| Covis Pharma GmbH | 10 | $151 |
| Circassia Inc. | 2 | $117 |
| Teva Pharmaceuticals USA, Inc. | 5 | $76 |
| Incyte Corporation | 4 | $69 |
| GC Biopharma USA, Inc. | 3 | $64 |
| Shire North American Group Inc | 4 | $61 |
| Aimmune Therapeutics, Inc. | 3 | $61 |
| Galderma Laboratories, L.p. | 3 | $54 |
| Hikma Pharmaceuticals USA | 3 | $50 |
| Organon | 3 | $46 |
| Azurity Pharmaceuticals, Inc. | 1 | $28 |
| Nestle Healthcare Nutrition Inc. | 1 | $24 |
| AbbVie | 1 | $22 |
| Merck | 1 | $20 |
| Mylan Specialty L.p. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,158 in reported general payments places this provider in the 75th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XembifyImmune Globulin,gamma(Igg)klhw | 27 | $135,303 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $104,353 |
| Dupixent PenDupilumab | 25 | $89,375 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 22 | $65,608 |
| TezspireTezepelumab-Ekko | 15 | $61,206 |
| Dupixent SyringeDupilumab | 12 | $47,008 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $30,927 |
| XhanceFluticasone Propionate | 21 | $11,774 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $8,143 |
| DuleraMometasone/Formoterol | 12 | $8,121 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $5,425 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,603 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 22 | $4,271 |
| Epinephrine | 22 | $3,110 |
| Arnuity ElliptaFluticasone Furoate | 14 | $2,835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCXembify | $760 | $135,30327 claims |
| CSL BehringHizentra | $1,353 | $104,35312 claims |
| AstraZenecaTezspire, Symbicort | $3,297 | $65,80930 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $1,120 | $65,60822 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $2,276 | $41,90570 claims |
| Optinose US, Inc.Xhance | $1,000 | $11,77421 claims |
| MerckDulera | $20 | $8,12112 claims |
| Hikma Pharmaceuticals USAEpinephrine | $50 | $3,11022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Charlotte
- Maeve OconnorCharlotte$2.2M
- Roopen PatelCharlotte$257K
- John NorrisCharlotte$198K
- Vandana PatelCharlotte$105K
- Jennifer CaicedoCharlotte$50K
- Richard CollinsCharlotte$28K
- Shannon ChadhaCharlotte$22K
- Bailee GilchristCharlotte$20K
- Susan HungnessCharlotte$17K
- Michael LapuenteCharlotte$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.